Xiaomi Just Took Aim at Apple and Tesla -- And It's Not Backing Down
Xiaomi (XIACY) just fired a shot at two of the world's most valuable companies and it wasn't subtle. At a splashy product launch in China, CEO Lei Jun unveiled the 15S Pro smartphone, priced at just 5,499 yuan ($764), making it eligible for a government subsidy. That's well below the iPhone 16 Pro's 7,999 yuan starting point a critical price edge in a country where the 6,000 yuan threshold unlocks discounts for consumers. More importantly, Lei claimed Xiaomi's homegrown chip, the Xring O1, beats Apple's (NASDAQ:AAPL) A18 Pro in key areas like thermal performance during gaming. It took four years and $1.87 billion to develop and it's already in mass production using the same 3nm process that powers Apple's flagship.
Warning! GuruFocus has detected 6 Warning Signs with XIACY.
But phones are just the warm-up act. Xiaomi's real ambition might be on four wheels. After undercutting Tesla (NASDAQ:TSLA) last year with its SU7 sedan priced $4,000 lower than the Model 3 the company is now preparing to launch the YU7 SUV in July. Lei didn't reveal pricing, but he did drop a few details: the YU7 will feature chips from Qualcomm and Nvidia, advanced driver assist, and up to 835 km of range. Still, the road hasn't been smooth. A fatal SU7 crash triggered tighter ad rules on driver-assist features. Despite that, Xiaomi delivered 28,000 vehicles in April and shows no signs of slowing down.
Investors will get their next read on May 27, when Xiaomi reports Q1 results. Last year, it posted record revenue and profit, with nearly 42% of sales coming from overseas markets. The stock is already up over 50% year-to-date and with Lei pledging 200 billion yuan in R&D through 2031, the market may be starting to realize: this isn't just a phone company anymore. Xiaomi wants to play in every arena Apple and Tesla dominate and it's bringing its own chips, cars, and pricing power to the fight.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@
Yahoo
33 minutes ago
- Yahoo
Why Guardant Health Stock Surged Nearly 9% Higher Today
The company's Shield multi-cancer detection test won an important designation from a top regulator. This should help bring it to market quicker. 10 stocks we like better than Guardant Health › Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. This made it quite the outperformer on the exchange, as the bellwether S&P 500 index's gain was a relatively modest 0.6%. This morning before market open, Guardant announced that the U.S. Food and Drug Administration (FDA) had granted the healthcare company's Shield multi-cancer detection (MCD) test its Breakthrough Device designation. This instantly confers a high status on Shield, as the FDA's designation is given only to a small clutch of medical devices that can either diagnose or treat a disease more effectively than other products. In Shield's case, it is quite a versatile diagnostic device that can screen for a wide range of cancers, including colorectal, lung, and ovarian. It is designed to evaluate people 45 years of age or older who are at a typical average risk for cancer. According to Guardant, Shield has 98.6% specificity and 75% sensitivity in detecting certain cancers. In its news release touting the FDA's move, Guardant quoted its co-CEO AmirAli Talasaz as saying that it "shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw." "We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly," he added. Another big plus of the Breakthrough Device designation is that it's part of an FDA initiative aimed at getting useful medical products to market faster. Talasaz and his team at Guardant might just get their wish with Shield before long. Before you buy stock in Guardant Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Guardant Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health. The Motley Fool has a disclosure policy. Why Guardant Health Stock Surged Nearly 9% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Atlantic
41 minutes ago
- Atlantic
One App to Rule Them All
If Google has its way, there will be no search bars, no search terms, no searching (at least not by humans). The very tool that has defined the company—and perhaps the entire internet—for nearly three decades could soon be overtaken by a chatbot. Last month, at its annual software conference, Google launched 'AI Mode,' the most drastic overhaul to its search engine in the company's history. The feature is different from the AI summaries that already show up in Google's search results, which appear above the usual list of links to outside websites. Instead, AI Mode functionally replaces Google Search with something akin to ChatGPT. You ask a question and the AI spits out an answer. Instead of sifting through a list of blue links, you can just ask a follow-up. Google has begun rolling out AI Mode to users in the U.S. as a tab below the search bar (before 'Images,' 'Shopping,' and the like). The company said it will soon introduce a number of more advanced, experimental capabilities to AI Mode, at which point the feature could be able to write a research report in minutes, 'see' through your smartphone's camera to assist with physical tasks such as a DIY crafts project, help book restaurant reservations, make payments. Whether AI Mode can become as advanced and as seamless as Google promises remains far from certain, but the firm appears to be aiming for something like an everything app: a single tool that will be able to do just about everything a person could possibly want to do online. Seemingly every major tech company is after the same goal. OpenAI markets ChatGPT, for instance, as able to write code and summarize documents, help shop, produce graphics, and, naturally, search the web. Elon Musk is notoriously obsessed with the idea of turning X into an everything app. Meta says you can use its AI 'for everything you need'; Amazon calls its new, generative AI–powered Alexa+ 'an assistant available to help any time you want'; Microsoft bills its AI Copilot as a companion 'for all you do'; and Apple has marketed Apple Intelligence and a revamped Siri as tools that will revolutionize how people use their iPhones (which encompass, for many users, everything). Even Airbnb, once focused simply on vacation rentals, is redesigning itself as a place where 'you can sell and do almost anything,' as its CEO, Brian Chesky, recently said. In a sense, everything apps are the logical conclusion of Silicon Valley's race to build artificial 'general' intelligence, or AGI. A bot smart enough to do anything obviously would be used to power a product that can, in effect, do anything. But such apps would also represent the culmination of the tech industry's aim to entrench its products in daily lives. Already, Google has features for shopping, navigation, data storage, work software, payment, travel—plus an array of smartphones, tablets, smart-home gadgets, and more. Apple has a similarly all-encompassing suite of offerings, and Meta's three major apps (Facebook, Instagram, and WhatsApp) each have billions of users. Perhaps the only thing more powerful than these sprawling tech ecosystems is boiling them all down to a single product. That these tech companies can even realistically have such colossal ambitions to build everything apps is a result of their existing dominance. The industry has spent years collecting information about our relationships, work, hobbies, and interests—all of which is becoming grist for powerful AI tools. A key feature of these everything apps is that they promise to be individually tailored, drawing on extensive personal data to provide, in theory, a more seamless experience. Your past search history, and eventually your emails, can inform AI Mode's responses: When I typed line up into AI Mode, I got the 'line up' for the day's New York Mets game (the Mets are my favorite baseball team). When I typed the same phrase into traditional Google Search, I got a definition. In other words, the rise of AI-powered everything apps is a version of the bargain that tech companies have proposed in the past with social media and other tools: our services for your data. Meta's AI assistant can draw on information from users' Facebook and Instagram accounts. Apple describes its AI as a 'personal intelligence' able to glean from texts, emails, and notes on your device. And ChatGPT has a new 'memory' feature that allows the chatbot to reference all previous conversations. If the technology goes as planned, it leads to a future in which Google, or any other Big Tech company, knows you are moving from Texas to Chicago and, of its own accord, offers to order the winter jacket you don't own to be delivered to your new apartment, already selected from your favorite brand, in your favorite color. Or it could, after reading emails musing about an Italian vacation, suggest an in-budget itinerary for Venice that best fits your preferences. There is, of course, no shortage of reasons to think that AI models will not be capable and reliable enough to power a true everything app. The Mets lineup that Google automatically generated for me wasn't entirely accurate. Chatbots still invent information and mess up basic math; concerns over AI's environmental harms and alleged infringement of intellectual-property rights could substantially slow the technology's development. Only a year ago, Google released AI Overviews, a search feature that told users to eat rocks and use glue to stick cheese to pizza. On the same day that Google released AI Mode, it also introduced an experimental AI shopping tool that can be easily used to make erotic images of teenagers, as I reported with my colleague Lila Shroff. (When we shared our reporting with the company, Google emphasized the protections it has in place and told us it would 'continue to improve the experience.') Maybe AI Mode will order something two sizes too large and ship to the wrong address, or maybe it'll serve you recommendations for Venice Beach. Despite these embarrassments, Google and its major AI competitors show no signs of slowing down. The promised convenience of everything apps is, after all, alluring: The more products of any one company you use, and the better integrated those products are, the more personalized and universal its everything app can be. Google even has a second contender in the race—its Gemini model, which, at the same conference, the company said will become a 'universal AI assistant.' Whether through Search or Gemini the company seems eager to integrate as many of its products and as much of its user data as possible. On the surface, AI and the everything app seem set to dramatically change how people interact with technology—consolidating and streamlining search, social media, officeware, and more into a chatbot. But a bunch of everything apps vying for customers feels less like a race for innovation and more like empires warring over territory. Tech companies are running the same data-hungry playbook with their everything apps as they did in the markets that made them so dominant in the first place. Even OpenAI, which has evolved from a little-known nonprofit to a Silicon Valley behemoth, appears so eager to accumulate user data that it reportedly plans to launch a social-media network. The technology of the future looks awfully reliant on that of the past.
